39089-30-0
Chemical Structure
Karacoline
- CAS No.: 39089-30-0
- Formula:C22H35NO4
- Molecular Weight:377.52
IUPAC Name: (3R,6S,7R,7aR,8S,9S,10S,11aS,14R)-1-ethyl-10-methoxy-3-methyltetradecahydro-11aH-3,6a,12-(epiethane[1,1,2]triyl)-7,9-methanonaphtho[2,3-b]azocine-6,8,11a-triol
InChIKey: HKQZUYOVMYOFIT-ZRNHKMHYSA-N
SMILES: O[C@@H]1C23C4C([C@]5(O)[C@]6([H])[C@@]3([H])C[C@@]([C@@H](OC)C5)([H])[C@@H]6O)C[C@]2([H])[C@@](CN4CC)(C)CC1
Biological Activity: Karacoline is an orally active PPARγ activator and ERK/JNK MAPK inhibitor. Karacoline restricts ROS production, maintains mitochondrial membrane potential, and inhibits pulmonary cell apoptosis. Karacoline inhibits NF-κB pathway activation, reduces acetylation levels of p65 and the expression of MMP14 and MMP9, enhances the expression of type II collagen (collagen II) and aggrecan (aggrecan), and suppresses extracellular matrix degradation. In a mouse model of sepsis-induced acute lung injury, Karacoline alleviates lung injury, inhibits the release of IL-1β, IL-6 and TNF-α, increases the Bcl-2/BAX ratio, and reduces caspase 3 expression. Karacoline can be used in research related to acute lung injury and intervertebral disc degeneration[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Karacoline | 99.58% | Karacoline is an orally active PPARγ activator and ERK/JNK MAPK inhibitor. Karacoline restricts ROS production, maintains mitochondrial membrane potential, and inhibits pulmonary cell apoptosis. Karacoline inhibits NF-κB pathway activation, reduces acetylation levels of p65 and the expression of MMP14 and MMP9, enhances the expression of type II collagen (collagen II) and aggrecan (aggrecan), and suppresses extracellular matrix degradation. In a mouse model of sepsis-induced acute lung injury, Karacoline alleviates lung injury, inhibits the release of IL-1β, IL-6 and TNF-α, increases the Bcl-2/BAX ratio, and reduces caspase 3 expression. Karacoline can be used in research related to acute lung injury and intervertebral disc degeneration. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Lei Z, et al. Karacoline attenuates sepsis-induced acute lung injury by suppressing apoptosis via PPARγ-associated inhibition of JNK/ERK MAPK signaling. Respiratory research. 2026 Jun 15. [Content Brief]
- [2]. Zhou X, et al. Karacoline, identified by network pharmacology, reduces degradation of the extracellular matrix in intervertebral disc degeneration via the NF-κB signaling pathway. Journal of pharmaceutical analysis. 2020 Feb;10(1):13-22. [Content Brief]
Keywords
